Findings seen among patients who undergo surgery and radiotherapy without chemotherapy<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, April 18, 2024 (HealthDay News) — For patients with early-stage triple-negative breast cancer (TNBC) who undergo surgery without chemotherapy, tumor-infiltrating lymphocyte (TIL) abundance is associated with improved survival, according to a study published online April 2 in the Journal of the American Medical Association<\/em>.<\/p>\n Roberto A. Leon-Ferre, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy in a retrospective pooled analysis of individual patient-level data from 13 participating centers. A total of 1,966 participants diagnosed with TNBC between 1979 and 2017 who received treatment with surgery, with or without radiotherapy but without chemotherapy, were included.<\/p>\n The researchers found that the median TIL level was 15 percent, and 417 (21 percent) and 1,300 (66 percent) patients had a TIL \u00e2\u0089\u00a550 percent and <30 percent, respectively. For stage I TNBC, five-year survival free of distant recurrence (DRFS) was 94 and 78 percent for those with a TIL level of \u00e2\u0089\u00a550 versus <30 percent, respectively; corresponding five-year overall survival was 95 versus 82 percent. After adjustment for age, tumor size, nodal status, histological grade, and receipt of radiotherapy, at a median follow-up of 18 years, each 10 percent higher TIL increment was independently associated with improved invasive disease-free survival, recurrence-free survival, DRFS, and overall survival (hazard ratios, 0.92, 0.90, 0.87, and 0.88, respectively).<\/p>\n “These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n